Did an iceberg just wallop into Conatus (CNAT) stock? This biotech company’s shares plunged yesterday at breakneck speed of almost 70%.
Conatus Pharmaceuticals Inc. (CNAT) stock fell over 50% today amid disappointing results for the company’s 2b ENCORE-PH clinical trial in NASH cirrhosis.
Nothing can kill a drug maker’s stock price like a failed clinical trial. Just take a look at the disaster that’s befallen Conatus …
Today, Conatus Pharmaceuticals (NASDAQ:CNAT) share price took a hit on the announcement that the drug maker’s POLT-HCV-SVR proof-of-concept clinical trial, in liver transplant patients …
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
Oppenheimer’s Jay Olson is optimistic about CNAT’s upside potential with the forthcoming topline data from the Phase 2 POLT study.
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 17% …
On Monday, Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that the FDA has granted Orphan Drug Designation to the company’s drug candidate IDN-7314, for the treatment …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced it has entered into an exclusive option, collaboration and license agreement for the global development and commercialization of …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that abstracts for four posters — two addressing clinical results and two addressing preclinical results with the company’s …